BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Thomas R. Staab II sold 11,198 shares of the stock in a transaction on Tuesday, November 20th. The stock was sold at an average price of $8.67, for a total value of $97,086.66. Following the sale, the insider now owns 137,458 shares in the company, valued at approximately $1,191,760.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of BCRX stock opened at $9.35 on Friday. The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 0.43. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.25 and a 52-week high of $9.70. The firm has a market capitalization of $1.01 billion, a P/E ratio of -11.99 and a beta of 1.75.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 141.00% and a negative net margin of 428.00%. The business had revenue of $1.45 million during the quarter, compared to analysts’ expectations of $2.53 million. On average, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.99 EPS for the current year.
BCRX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 13th. They noted that the move was a valuation call. JMP Securities increased their target price on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 5th. JPMorgan Chase & Co. initiated coverage on BioCryst Pharmaceuticals in a research report on Wednesday, August 8th. They set an “overweight” rating and a $9.00 target price on the stock. BidaskClub upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, October 16th. Finally, Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.75 target price on the stock in a research report on Tuesday, October 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. BioCryst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $10.53.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Further Reading: What is a bull market?
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.